Patient Perspectives of Bowel Urgency and Bowel Urgency-Related Accidents in Ulcerative Colitis and Crohn's Disease.

Crohn’s disease bowel urgency patient-reported outcomes ulcerative colitis

Journal

Inflammatory bowel diseases
ISSN: 1536-4844
Titre abrégé: Inflamm Bowel Dis
Pays: England
ID NLM: 9508162

Informations de publication

Date de publication:
21 Mar 2024
Historique:
received: 03 11 2023
medline: 22 3 2024
pubmed: 22 3 2024
entrez: 21 3 2024
Statut: aheadofprint

Résumé

Bowel urgency is bothersome in patients with ulcerative colitis (UC) or Crohn's disease (CD) and impacts their well-being but remains underappreciated in clinical trials and during patient-healthcare provider interactions. This study explored the experiences of bowel urgency and bowel urgency-related accidents to identify the concepts most relevant and important to patients. Adults with a diagnosis of moderate-to-severe UC or CD for ≥6 months and experience of bowel urgency in the past 6 months were included. Qualitative, semi-structured interviews were conducted via telephonic/Web-enabled teleconference. Interview transcripts were coded and analyzed in ATLAS.ti 9 using a systematic thematic analysis. In total, 30 participants with UC or CD (n = 15 each) (mean age 52 and 50 years, respectively) participated in the interviews. The majority of participants were receiving biologic and/or conventional therapy (80% and 87%, respectively). Most participants with UC (87%) and all with CD experienced bowel urgency-related accidents. The most frequently reported symptoms co-occurring with bowel urgency were abdominal pain, fatigue, and abdominal cramping. Abdominal pain and abdominal cramping were the most bothersome co-occurring symptoms of bowel urgency and bowel urgency-related accidents. In both groups, participants reported decreased frequency of bowel urgency and not wanting to experience bowel urgency-related accidents at all as a meaningful improvement. Participants with UC or CD expressed bowel urgency and bowel urgency-related accidents to be bothersome and impactful on their daily lives despite use of biologic and/or conventional therapy. These findings underscore the need for development of patient-reported outcome measures to assess bowel urgency in clinical settings. Bowel urgency and bowel urgency-related accidents are accompanied by several bothersome symptoms and considerably impact patients’ quality of life, highlighting the need to develop a patient-reported outcome measure for assessing and addressing bowel urgency in clinical settings.

Sections du résumé

BACKGROUND BACKGROUND
Bowel urgency is bothersome in patients with ulcerative colitis (UC) or Crohn's disease (CD) and impacts their well-being but remains underappreciated in clinical trials and during patient-healthcare provider interactions. This study explored the experiences of bowel urgency and bowel urgency-related accidents to identify the concepts most relevant and important to patients.
METHODS METHODS
Adults with a diagnosis of moderate-to-severe UC or CD for ≥6 months and experience of bowel urgency in the past 6 months were included. Qualitative, semi-structured interviews were conducted via telephonic/Web-enabled teleconference. Interview transcripts were coded and analyzed in ATLAS.ti 9 using a systematic thematic analysis.
RESULTS RESULTS
In total, 30 participants with UC or CD (n = 15 each) (mean age 52 and 50 years, respectively) participated in the interviews. The majority of participants were receiving biologic and/or conventional therapy (80% and 87%, respectively). Most participants with UC (87%) and all with CD experienced bowel urgency-related accidents. The most frequently reported symptoms co-occurring with bowel urgency were abdominal pain, fatigue, and abdominal cramping. Abdominal pain and abdominal cramping were the most bothersome co-occurring symptoms of bowel urgency and bowel urgency-related accidents. In both groups, participants reported decreased frequency of bowel urgency and not wanting to experience bowel urgency-related accidents at all as a meaningful improvement.
CONCLUSIONS CONCLUSIONS
Participants with UC or CD expressed bowel urgency and bowel urgency-related accidents to be bothersome and impactful on their daily lives despite use of biologic and/or conventional therapy. These findings underscore the need for development of patient-reported outcome measures to assess bowel urgency in clinical settings.
Bowel urgency and bowel urgency-related accidents are accompanied by several bothersome symptoms and considerably impact patients’ quality of life, highlighting the need to develop a patient-reported outcome measure for assessing and addressing bowel urgency in clinical settings.

Autres résumés

Type: plain-language-summary (eng)
Bowel urgency and bowel urgency-related accidents are accompanied by several bothersome symptoms and considerably impact patients’ quality of life, highlighting the need to develop a patient-reported outcome measure for assessing and addressing bowel urgency in clinical settings.

Identifiants

pubmed: 38513272
pii: 7633225
doi: 10.1093/ibd/izae044
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Eli Lilly and Company

Informations de copyright

© 2024 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation.

Auteurs

Vipul Jairath (V)

Division of Gastroenterology, Department of Medicine, Western University, London, Ontario, OX3 9DU, Canada.

Theresa Hunter Gibble (T)

Eli Lilly and Company, Indianapolis, IN, USA.

Alison Potts Bleakman (A)

Eli Lilly and Company, Indianapolis, IN, USA.

Kaitlin Chatterton (K)

Patient-Centered Outcomes, Adelphi Values, Boston, Massachusetts, USA.

Paolo Medrano (P)

Patient-Centered Outcomes, Adelphi Values, Boston, Massachusetts, USA.

Megan McLafferty (M)

Patient-Centered Outcomes, Adelphi Values, Boston, Massachusetts, USA.

Brittany Klooster (B)

Patient-Centered Outcomes, Adelphi Values, Boston, Massachusetts, USA.

Sonal Saxena (S)

Eli Lilly and Company, Indianapolis, IN, USA.

Richard Moses (R)

Eli Lilly and Company, Indianapolis, IN, USA.

Classifications MeSH